文献速递临床试验与 GCP流行病学与生物统计

被动免疫治疗用于COVID-19住院成人:六项随机对照试验的个体参与者数据荟萃分析

Passive immunotherapy for adults hospitalized with COVID-19: An individual participant data meta-analysis of six randomized controlled trials.
PubMed 文献 · PLoS Med · 2025-07-07

该研究对六项双盲随机安慰剂对照试验进行个体参与者数据荟萃分析,共纳入3079例COVID-19住院成人。治疗组与安慰剂组持续恢复率比总体为1.06(95%CI [0.99,1.14]),在血清阴性患者中为1.16(95%CI [1.04,1.29]),血清阳性患者中为0.97(95%CI [0.88,1.07]),交互作用p=0.02。被动免疫治疗可能对在内源性抗体出现前给药的住院患者有用。

要点

  • 血清阴性患者持续恢复率比1.16(95%CI [1.04,1.29]),血清阳性患者0.97(95%CI [0.88,1.07]),交互作用p=0.02。
  • 总体死亡率风险比0.81(95%CI [0.64,1.03]),血清阴性患者0.69(95%CI [0.50,0.95]),血清阳性患者0.96(95%CI [0.66,1.39]),交互作用p=0.18。
  • 复合安全性结局总体风险比0.89(95%CI [0.66,1.21];Q=3.47,p=0.63,I²=0.0%)。

核心结论

  • 被动免疫治疗若在内源性抗体出现前给药,可能对COVID-19住院患者是有用的治疗选择。
  • 开发类似的被动免疫治疗在病毒大流行早期或新病毒变异株出现时也可能尤为重要。

研究设计与样本

  • 研究为两阶段个体参与者数据荟萃分析,纳入六项在COVID-19住院患者治疗(TICO)和住院患者抗冠状病毒免疫球蛋白治疗(ITAC)主方案下开展的双盲、随机、安慰剂对照试验。
  • 共纳入3079例COVID-19住院患者,仅18%接受过至少一剂抗SARS-CoV-2疫苗。
  • 研究纳入时血浆SARS-CoV-2抗原水平中位数为1421(IQR:231-4568)pg/mL,51%患者内源性中和抗体阳性。
  • 在每个试验内使用Fine-Gray和Cox比例风险模型比较治疗与安慰剂的三个主要结局,试验特异性治疗差异采用共同效应荟萃分析合并。

主要发现

  • 治疗组与安慰剂组持续恢复率比总体汇总估计为1.06(95%CI [0.99,1.14]),但按抗体血清状态存在显著差异。
  • 血清阴性患者持续恢复率比为1.16(95%CI [1.04,1.29]),血清阳性患者为0.97(95%CI [0.88,1.07]),交互作用p=0.02。
  • 治疗组与安慰剂组死亡率汇总风险比总体为0.81(95%CI [0.64,1.03]),血清阴性患者为0.69(95%CI [0.50,0.95]),血清阳性患者为0.96(95%CI [0.66,1.39]),交互作用p=0.18。
  • 无证据表明治疗对任何结局的效应按抗原水平存在差异,无论是总体还是在血清状态亚组内。
  • 复合安全性结局治疗组与安慰剂组总体汇总风险比为0.89(95%CI [0.66,1.21];Q=3.47,p=0.63,I²=0.0%),血清阴性患者为0.83(95%CI [0.70,0.99]),血清阳性患者为1.04(95%CI [0.86,1.26])。

临床怎么用

  • 作者认为,被动免疫治疗若在内源性抗体出现前给药,可能对COVID-19住院患者是有用的治疗选择。

局限性

  • 方法学的主要局限性是这些结果仅限于对ACTIV-3/TICO和ITAC中六项试验的分析,并非所有被动免疫治疗试验的完整总结。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anti-SARS-CoV-2 monoclonal antibodies (mAb) reduce the risk of hospitalization in outpatients with mild-to-moderate COVID-19. However, the efficacy of treatment with mAbs and other passive immunotherapies in patients hospitalized with severe COVID-19 is not clear. The objective of this study was to assess the clinical effect of passive immunotherapy and its heterogeneity according to baseline endogenous neutralizing antibody status and SARS-CoV-2 antigen level, in adults hospitalized with SARS-CoV-2 infection and severe COVID-19. METHODS AND FINDINGS: We carried out a two-stage individual participant data meta-analysis of six double-blind, randomized, placebo-controlled trials conducted under the Therapeutics for Inpatients with COVID-19 (TICO) and the similarly designed Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) master protocols. Within each trial, three major outcomes (sustained recovery, mortality, and a composite safety outcome) were compared between treatment and placebo using Fine-Gray and Cox proportional hazards models. Trial-specific treatment differences for each of the three outcomes were pooled using a common effect meta-analysis. A total of 3,079 patients hospitalized for COVID-19 were enrolled in the six trials. Only 18% had received at least one dose of an anti-SARS-CoV-2 vaccine. Overall, the median plasma SARS-CoV-2 antigen level was 1,421 (IQR: 231-4,568) pg/mL, and 51% of patients were endogenous neutralizing antibody positive at study entry. The overall summary estimate of sustained recovery rate ratio (RRR) of the treatment versus placebo group was 1.06 (95% CI [0.99,1.14]), but this varied significantly by antibody serostatus. The RRR was 1.16 (95% CI [1.04,1.29]) among seronegative patients and 0.97 (95% CI [0.88,1.07]) in seropositive patients [p = 0.02 for interaction (the difference in RRR between seropositive and seronegative patients)]. The summary hazard ratio (HR) for mortality comparing treatment to placebo was 0.81 (95% CI [0.64,1.03]) overall, 0.69 (95% CI [0.50,0.95]) in seronegative patients, and 0.96 (95% CI [0.66,1.39]) in seropositive patients (interaction p = 0.18). There was no evidence that the treatment effect on any outcome differed according to antigen level, whether overall or within serostatus subgroups. In regards to the composite safety outcome, the overall summary HR comparing treatment group to placebo was 0.89 (95% CI [0.66,1.21]; Q = 3.47 [p = 0.63], I2 = 0.0%), and it was 0.83 (95% CI [0.70,0.99]) and 1.04 (95% CI [0.86,1.26]) in seronegative and seropositive patients, respectively. The main limitation of the methodology is that these results are limited to the analysis of the six trials in ACTIV-3/TICO and ITAC and are not intended to be a complete summary of all trials of passive immunotherapy. CONCLUSIONS: Passive immunotherapy might be a useful treatment option for hospitalized patients with COVID-19 if administered before the appearance of endogenous antibodies. Development of similar passive immunotherapy could also be especially important during the early stages of a viral pandemic, or as novel viral variants emerge.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Knowlton KU, Siegel LK, Barkauskas CE, et al. Passive immunotherapy for adults hospitalized with COVID-19: An individual participant data meta-analysis of six randomized controlled trials. PLoS Med. 2025. PMID: 40623115. doi:10.1371/journal.pmed.1004616

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。